• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用效应量的荟萃分析比较成人注意缺陷多动障碍药物的疗效。

A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.

机构信息

Department of Psychiatry, SUNY Upstate Medical University, 750 East Adams St, Syracuse, NY 13210, USA.

出版信息

J Clin Psychiatry. 2010 Jun;71(6):754-63. doi: 10.4088/JCP.08m04902pur. Epub 2009 Dec 29.

DOI:10.4088/JCP.08m04902pur
PMID:20051220
Abstract

OBJECTIVES

Medications used to treat attention-deficit/hyperactivity disorder (ADHD) in adults have been well researched, but comparisons among drugs are hindered by the absence of direct comparative trials. Our objectives were to (1) estimate the effect size of the medications used to treat adult ADHD, (2) determine if differences in the designs of studies confound comparisons of medication efficacy, (3) quantify the evidence for differences in effect sizes among medications, and (4) see if features of study design influence estimates of efficacy.

DATA SOURCES

The following search engines were used: PubMed, Ovid, ERIC, CINAHL, MEDLINE, PREMEDLINE, the Cochrane database, e-psyche, and Social Sciences Abstracts. Presentations from the American Psychiatric Association and American Academy of Child and Adolescent Psychiatry meetings were reviewed.

STUDY SELECTION

A literature search was conducted to identify double-blind, placebo-controlled studies of ADHD in adults published in English after 1979. Only trials that used DSM-III, -III-R, or -IV ADHD criteria and followed subjects for > or = 2 weeks were selected.

DATA EXTRACTION

Meta-analysis regression assessed the influence of medication type and study design features on medication effects.

RESULTS

Nineteen trials met criteria and were included in this meta-analysis. These trials studied 13 drugs using 18 different outcome measures of hyperactive, inattentive, or impulsive behavior. After trials were stratified on the class of drug studied (short-acting stimulant vs long-acting stimulant vs nonstimulant), significant differences in effect size were observed between stimulant and nonstimulant medications (P = .006 and P = .0001, respectively, for short- and long-acting stimulants vs nonstimulants), but the effect for short-acting stimulants was not significant after correcting for study design features. The effect sizes for each drug class were similar in magnitude to what we previously reported for medication treatment studies of children with ADHD. We found significant heterogeneity of effect sizes for short-acting stimulants (P < .001) but not for other medication groups.

CONCLUSIONS

Although both stimulant and nonstimulant medications are effective for treating ADHD in adults, stimulant medications show greater efficacy for the short durations of treatment characteristic of placebo-controlled studies. We found no significant differences between short- and long-acting stimulant medications. Study design features vary widely among studies and can confound indirect comparisons unless addressed statistically as we have done in this study.

摘要

目的

用于治疗成人注意缺陷多动障碍(ADHD)的药物已有充分研究,但由于缺乏直接比较试验,药物之间的比较受到阻碍。我们的目标是:(1)评估用于治疗成人 ADHD 的药物的效应大小,(2)确定研究设计的差异是否混淆药物疗效的比较,(3)量化药物之间效应大小差异的证据,(4)观察研究设计特征是否影响疗效的估计。

资料来源

使用了以下搜索引擎:PubMed、Ovid、ERIC、CINAHL、MEDLINE、PREMEDLINE、Cochrane 数据库、e-psyche 和社会科学文摘。审查了美国精神病学协会和美国儿童和青少年精神病学学会会议的报告。

研究选择

进行了文献检索,以确定 1979 年后发表的用英语撰写的治疗成人 ADHD 的双盲、安慰剂对照研究。仅选择使用 DSM-III、-III-R 或 -IV ADHD 标准并随访受试者>或=2 周的试验。

资料提取

荟萃分析回归评估了药物类型和研究设计特征对药物作用的影响。

结果

19 项试验符合标准并纳入本荟萃分析。这些试验研究了 13 种药物,使用了 18 种不同的多动、注意力不集中或冲动行为的结果测量。在按研究药物类别分层(短效兴奋剂与长效兴奋剂与非兴奋剂)后,观察到兴奋剂和非兴奋剂药物之间的效应大小存在显著差异(短效兴奋剂与非兴奋剂相比,P=.006 和 P=.0001;长效兴奋剂与非兴奋剂相比,P=.006 和 P=.0001),但在校正研究设计特征后,短效兴奋剂的作用不显著。每种药物类别的效应大小与我们之前报告的 ADHD 儿童药物治疗研究相似。我们发现短效兴奋剂的效应大小存在显著异质性(P<.001),但其他药物组没有。

结论

尽管兴奋剂和非兴奋剂药物对治疗成人 ADHD 均有效,但兴奋剂药物在安慰剂对照研究中治疗时间较短的情况下显示出更大的疗效。我们没有发现短效和长效兴奋剂药物之间的显著差异。研究设计特征在研究之间差异很大,如果不像我们在本研究中那样进行统计学处理,可能会混淆间接比较。

相似文献

1
A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.采用效应量的荟萃分析比较成人注意缺陷多动障碍药物的疗效。
J Clin Psychiatry. 2010 Jun;71(6):754-63. doi: 10.4088/JCP.08m04902pur. Epub 2009 Dec 29.
2
Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.注意缺陷多动障碍患者的药物治疗模式:基于管理式医疗人群的回顾性理赔数据分析。
Curr Med Res Opin. 2010 Apr;26(4):977-89. doi: 10.1185/03007991003673617.
3
Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.混合安非他明盐缓释剂(阿得拉XR)治疗青少年注意缺陷多动障碍的疗效与安全性:一项为期4周的随机、双盲、安慰剂对照平行组研究。
Clin Ther. 2006 Feb;28(2):266-79. doi: 10.1016/j.clinthera.2006.02.011.
4
Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.莫达非尼可改善儿童和青少年各亚型注意缺陷多动障碍的症状。
J Pediatr. 2008 Mar;152(3):394-9. doi: 10.1016/j.jpeds.2007.07.052. Epub 2007 Oct 24.
5
Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.儿童注意力缺陷多动障碍治疗的演变:综述
Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006.
6
A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.一项为期18天的随机对照试验的事后亚组分析,该试验比较了缓释混合苯丙胺盐和托莫西汀在患有注意力缺陷/多动障碍的学龄女童中的耐受性和疗效。
Clin Ther. 2006 Feb;28(2):280-93. doi: 10.1016/j.clinthera.2006.02.008.
7
Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.共病自闭症谱系障碍对注意力缺陷多动障碍儿童兴奋剂反应的影响:一项回顾性和前瞻性有效性研究。
Child Care Health Dev. 2006 Sep;32(5):575-83. doi: 10.1111/j.1365-2214.2006.00631.x.
8
Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.盐酸托莫西汀治疗患有注意力缺陷/多动障碍及共病对立违抗性障碍的儿童和青少年:一项意大利的安慰剂对照研究。
Eur Neuropsychopharmacol. 2009 Nov;19(11):822-34. doi: 10.1016/j.euroneuro.2009.07.008. Epub 2009 Aug 28.
9
Attention-deficit-hyperactivity disorder: an update.注意缺陷多动障碍:最新进展
Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656.
10
Duration of effect of oral long-acting stimulant medications for ADHD throughout the day.ADHD 口服长效兴奋剂药物一整天的药效持续时间。
Curr Med Res Opin. 2010 Aug;26(8):1809-25. doi: 10.1185/03007995.2010.488553.

引用本文的文献

1
Causal relationship between attention deficit hyperactivity disorder and atherosclerosis: A bidirectional Mendelian randomization study.注意缺陷多动障碍与动脉粥样硬化之间的因果关系:一项双向孟德尔随机化研究。
Medicine (Baltimore). 2025 Jun 27;104(26):e42859. doi: 10.1097/MD.0000000000042859.
2
Training of Awareness in ADHD: Leveraging Metacognition.注意缺陷多动障碍中的意识训练:利用元认知
J Psychiatr Brain Sci. 2024;9(5). doi: 10.20900/jpbs.20240006. Epub 2024 Oct 9.
3
Attention-deficit/hyperactivity disorder (ADHD) in adults: a multilayered approach to a serious disorder of inattention to the future.
成人注意缺陷多动障碍(ADHD):一种针对未来注意力不集中严重障碍的多层次方法。
Arq Neuropsiquiatr. 2024 Jul;82(7):1-12. doi: 10.1055/s-0044-1791513. Epub 2024 Oct 2.
4
Investigating the Impact of Nutrition and Oxidative Stress on Attention Deficit Hyperactivity Disorder.探讨营养与氧化应激对注意缺陷多动障碍的影响。
Nutrients. 2024 Sep 15;16(18):3113. doi: 10.3390/nu16183113.
5
Categorical and dimensional aspects of stimulant medication effects in adult patients with ADHD and healthy controls.多动症成年患者和健康对照中兴奋剂药物疗效的分类和维度方面。
Front Pharmacol. 2024 Jul 10;15:1412178. doi: 10.3389/fphar.2024.1412178. eCollection 2024.
6
Sociodemographic and Clinical Factors Affecting Treatment Adherence in Adults with Attention Deficit and Hyperactivity Disorder.影响成人注意力缺陷多动障碍治疗依从性的社会人口学和临床因素
Psychiatry Clin Psychopharmacol. 2022 Jun 1;32(2):107-117. doi: 10.5152/pcp.2022.21156. eCollection 2022 Jun.
7
Glutamate imbalance in key structure of the default mode network in adults with attention-deficit/hyperactivity disorder.注意缺陷多动障碍成人默认模式网络关键结构中的谷氨酸失衡
Eur Arch Psychiatry Clin Neurosci. 2024 May 16. doi: 10.1007/s00406-024-01805-z.
8
Trends in Use of Telemedicine for Stimulant Initiation Among Children and Adults.儿童和成人中使用远程医疗启动兴奋剂的趋势。
Psychiatr Serv. 2024 Jul 1;75(7):630-637. doi: 10.1176/appi.ps.20230421. Epub 2024 Jan 19.
9
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder.缓释维洛沙嗪与托莫西汀治疗注意缺陷多动障碍的比较。
CNS Drugs. 2023 Jul;37(7):655-660. doi: 10.1007/s40263-023-01023-6. Epub 2023 Jul 10.
10
Evaluation of the effectiveness of the FOCUS ADHD App in monitoring adults with attention-deficit/hyperactivity disorder.评估 FOCUS ADHD 应用程序在监测成人注意力缺陷/多动障碍中的有效性。
Eur Psychiatry. 2023 Jun 21;66(1):e53. doi: 10.1192/j.eurpsy.2023.2422.